



**AMENDMENTS TO THE CLAIMS**

1. (Currently amended) A method of increasing expression of a molecular chaperone by ~~an~~ a eukaryotic cell comprising:

treating ~~an~~ a eukaryotic cell of a living mammalian organism that is exposed to a physiological stress accompanying allergic diseases, immune diseases, autoimmune diseases, diseases of viral or bacterial origin, tumorous, skin and/or mucous diseases, epithelial disease of renal tubulus, atherosclerosis, coronarial disease, pulmonary hypertonia, cerebrovascular ischemia, stroke, or traumatic head injury, with an effective amount of a chemical compound to increase the expression of the molecular chaperone by the cell beyond the amount induced by the physiological stress, wherein the chemical compound is selected from one or more of a hydroxylamine derivatives represented by formula (II),





or a salt thereof or any optically active stereoisomer thereof, wherein  
A is an alkyl, substituted alkyl, aralkyl, aralkyl substituted in the aryl and/or alkyl moiety, aryl, substituted aryl, heteroaryl or substituted heteroaryl group,  
Z is a covalent bond, oxygen or =NR<sup>3</sup>, wherein R<sup>3</sup> is selected from the group consisting of hydrogen, an alkyl, substituted alkyl, aryl, substituted aryl, aralkyl and aralkyl substituted in the aryl and/or alkyl moiety,  
R is alkyl or substituted alkyl, and

X is oxygen, an imino or substituted imino group, and

R' is hydrogen, an alkyl, substituted alkyl, aryl, substituted aryl, aralkyl, aralkyl  
~~having~~ substituted in the aryl or alkyl moiety, acyl or substituted acyl  
group.



2. (Original) The method according to claim 1 wherein the cell is treated before the physiological stress.
3. (Original) The method according to claim 1 wherein the cell is treated after the physiological stress.
4. (Original) The method of claim 1, wherein the mammalian cell is a human cell.
5. (Currently amended) The method of claim 1 wherein the cell is a neuronal cell, a muscle cell, a vessel wall cell, an epithelial cell or a cell of the immune system.
6. (Original) The method of claim 1 wherein the physiological stress is a metabolic, oxidative or local mechanical stress or a stress caused by hypoxia, heat shock, radiation or one or more toxic materials.
7. (Original) The method of claim 1 wherein the physiological stress causes an increase of reactive free radicals or a cytokine present in the area surrounding the cell.
8. (Currently amended) The method of claim 1, wherein one or more of the skin or mucosal disease is caused by dermatosis or ulcerous disease of the gastrointestinal system provoked by the physiological stress.
9. (Currently amended) The method of claim 1 wherein the molecular chaperone is a heat shock protein (hsp).
10. (Original) The method of claim 9 wherein the hsp is hsp70 or hsp72.
11. (Currently amended) A method of increasing activity of a molecular chaperone in an a eukaryotic cell that is exposed to a physiological stress comprising:  
treating the cell that is exposed to a physiological stress accompanying allergic diseases, immune diseases, autoimmune diseases, diseases of viral or bacterial

origin, tumorous, skin and/or mucous diseases, epithelial disease of renal tubulus, atherosclerosis, coronarial disease, pulmonary hypertonia, cerebrovascular ischemia, stroke, or traumatic head injury, with an effective amount of a chemical compound to increase the activity of the molecular chaperone in the cell beyond the amount induced by the physiological stress, wherein the chemical compound is selected from one or more of a hydroxylamine derivatives represented by formula (II),



or a salt thereof or an optically active stereoisomer thereof,  
wherein A is an alkyl, substituted alkyl, aralkyl, aralkyl substituted in the aryl and/or alkyl moiety, aryl, substituted aryl, heteroaryl or substituted heteroaryl group,  
Z is a covalent bond, oxygen or =NR<sup>3</sup>, wherein R<sup>3</sup> is selected from the group consisting of hydrogen, an alkyl, substituted alkyl, aryl, substituted aryl, aralkyl group and an aralkyl group substituted in the aryl and/or alkyl moiety,  
R is an alkyl or substituted alkyl group,  
X is oxygen, an imino or substituted imino group, and  
R' is hydrogen, an alkyl, substituted alkyl, aryl, substituted aryl, aralkyl, aralkyl ~~having~~ substituted in the aryl or alkyl moiety, acyl or substituted acyl group.

12. (Currently amended) The method of claim 11 wherein the physiological stress is a metabolic, oxidative or local mechanical stress or a stress caused by hypoxia, heat shock, radiation or one or more toxic materials.
13. (Original) The method of claim 11 wherein the physiological stress causes an increase of reactive free radicals or a cytokine present in the area surrounding the cell.
14. (Currently amended) The method of claim 11 wherein one or more of the skin or mucosal disease is caused by dermatosis or ulcerous disease of the gastrointestinal system provoked by the physiological stress.
15. (Currently amended) The method of claim 11 wherein the molecular chaperone is a heat shock protein (hsp).
16. (Original) The method of claim 15 wherein the hsp is hsp70 or hsp72.
17. (Currently amended) A method of treating a disease connected with the function of the chaperone system or associated with the injury of the membrane of a cell or cell organelle or preventing the same which comprises:
  - administering to a host that has been exposed to a physiological stress accompanying allergic diseases, immune diseases, autoimmune diseases, diseases of viral or bacterial origin, tumorous, skin and/or mucous diseases, epithelial disease of renal tubulus, atherosclerosis, coronarial disease, pulmonary hypertonia, cerebrovascular ischemia, stroke, or traumatic head injury, an effective amount of a chemical compound to increase the expression of a molecular chaperone by cells of the host beyond an amount induced by the physiological stress to ameliorate the effect caused by the pathological condition in the organism, wherein the chemical compound is ~~one or more of a~~ selected from hydroxylamine derivatives represented by formula (II),



or a salt thereof or an optically active stereoisomer thereof, wherein  
 A is an alkyl, substituted alkyl, aralkyl, aralkyl substituted in the aryl and/or alkyl moiety, aryl, substituted aryl, heteroaryl or substituted heteroaryl group,  
 Z is a covalent bond, oxygen or =NR<sup>3</sup>, wherein R<sup>3</sup> is selected from the group consisting of hydrogen, an alkyl, substituted alkyl, aryl, substituted aryl, aralkyl and aralkyl substituted in the aryl and/or alkyl moiety,  
 R is an alkyl or substituted alkyl, and  
 X is oxygen, an imino or substituted imino group, and  
 R' is hydrogen, an alkyl, substituted alkyl, aryl, substituted aryl, aralkyl, aralkyl having a substituted aryl or alkyl moiety, acyl or substituted acyl group.

18. (Original) The method of claim 17, wherein the pathological condition is selected from the group consisting of a neoplastic disease, an infection caused by a pathogenic microorganism, an autoimmune disease and dermatosis.
19. (Original) The method of claim 17 wherein the host is a human organism.
20. (Currently amended) The method according to claim 17, wherein
  - R is an alkyl or substituted alkyl group, and
  - a) Z is chemical bond and X is oxygen, ~~or~~ ;
  - b) Z is chemical bond and X is =NR<sup>4</sup> wherein R<sup>4</sup> is H or an unsubstituted or substituted alkyl or cycloalkyl group, ~~or~~ ;

- c) Z is oxygen and X is oxygen~~;~~ ;
- d) Z is oxygen and X is =NR<sup>4</sup> wherein R<sup>4</sup> is an unsubstituted or substituted alkyl, unsubstituted or substituted aralkyl, unsubstituted or substituted aryl, or heteroaryl group~~;~~ ;
- e) Z is =NR<sup>3</sup>, wherein R<sup>3</sup> is H; or an unsubstituted or substituted alkyl, aryl or aralkyl group, and X is oxygen~~;~~ ;
- f) Z is =NR<sup>3</sup>, wherein R<sup>3</sup> is H, an unsubstituted or substituted alkyl, aryl or aralkyl and X is =NR<sup>4</sup>, wherein R<sup>4</sup> is H, an unsubstituted or substituted alkyl or aralkyl, or cycloalkyl group.
21. (Original) The method of claim 20 wherein R is an  $\omega$ -amino-alkyl which may be substituted on the amino and/or alkyl group, and wherein the alkyl chain contains 3 to 8 carbon atoms and is straight or branched, and can be substituted with hydroxy or acyloxy.
22. (Original) The method of claim 20 wherein R is an  $\omega$ -amino-alkyl mono- or disubstituted on the amino, wherein the disubstituted amino substituents, are independently one or two straight or branched alkyl or cycloalkyl, or the disubstituted amino substituents, together with the nitrogen atom attached thereto, form a 3 to 7-membered saturated hetero ring, which may contain additional hetero atom(s).
23. (Currently amended) The method according to claim 20, wherein  
Z is a chemical bond,  
X is oxygen,  
R' is H, an unsubstituted or substituted straight or branched alkyl, unsubstituted or substituted aryl, aralkyl, or aralkyl substituted in the aryl and/or alkyl moiety, and  
A is an unsubstituted or substituted aryl or aralkyl, or heteroaryl group.
24. (Currently amended) The method of claim 23 wherein A is  
a) phenyl~~;~~ ;  
b) phenyl substituted with one or more alkyl, haloalkyl or alkoxy~~;~~ ;  
c) aralkyl~~;~~ ;

- d) aralkyl substituted in one or more of the aryl or alkyl moiety~~,-or~~ ;
- e) N-containing heteroaryl<sub>1</sub>; or
- f) S-containing heteroaryl.

25. (Currently amended) The method according to claim 20, wherein

Z is chemical bond,

X is =NR<sup>4</sup>, wherein R<sup>4</sup> is H, an unsubstituted or substituted straight or branched alkyl, unsubstituted or substituted aryl, aralkyl, aralkyl substituted in the aryl and/or alkyl moiety, or cycloalkyl group,

R' is an unsubstituted or substituted straight or branched alkyl, unsubstituted or substituted aryl, aralkyl group or an aralkyl group substituted in the aryl and/or alkyl moiety, and

A is an aralkyl, aralkyl substituted in the aryl and/or alkyl moiety, unsubstituted or substituted aryl or heteroaryl group.

26. (Currently amended) The method of claim 25 wherein A is

- a) phenylalkyl~~,-or~~ ;
- b) phenylalkyl substituted with one or more alkoxy in the phenyl moiety~~,-or~~ ;
- c) phenyl~~,-or~~ ;
- d) phenyl substituted with one or more alkyl, haloalkyl or nitro~~,-or~~ ;
- e) naphthyl~~,-or~~ ;
- f) N-containing heteroaryl<sub>1</sub>; or
- g) ~~an~~ S-containing heteroaryl.

27. (Currently amended) The method according to claim 20 wherein

Z is oxygen,

X is oxygen,

R' is H, an unsubstituted or substituted straight or branched alkyl, unsubstituted or substituted aryl, aralkyl, or aralkyl group substituted in the aryl and/or alkyl moiety, and

A is an unsubstituted or substituted straight or branched alkyl, aralkyl group, or an aralkyl group substituted in one or both of the aryl or alkyl moiety.


28. (Currently amended) The method according to claim 20 wherein Z is oxygen and X is  $=NR^4$ , wherein  $R^4$  is an unsubstituted or substituted straight or branched alkyl, aralkyl, aralkyl substituted in the aryl and/or alkyl moiety, unsubstituted or substituted phenyl or unsubstituted or substituted heteroaryl group, and  $R'$  is an unsubstituted or substituted straight or branched alkyl, unsubstituted or substituted aryl, aralkyl group, or aralkyl group substituted in the aryl and/or alkyl moiety.
29. (Currently amended) The method according to claim 20, wherein  
Z is  $=NR^3$ ,  
 $R^3$  is H, an unsubstituted or substituted straight or branched alkyl, unsubstituted or substituted aryl, aralkyl group, or an aralkyl group substituted in the aryl and/or alkyl moiety,  
X is oxygen,  
 $R'$  is H, an unsubstituted or substituted straight or branched alkyl, unsubstituted or substituted aryl, aralkyl, or aralkyl substituted in the aryl and/or alkyl moiety, or acyl group, and  
A is an unsubstituted or substituted alkyl, aralkyl, aryl or heteroaryl or cycloalkyl group.
30. (Currently amended) The method according to claim 29 wherein A is  
a) unsubstituted or substituted straight or branched alkyl which contains 4 to 12 carbon atoms, ~~or~~ ;  
b) cycloalkyl, ~~or~~ ;  
c) unsubstituted or substituted phenylalkyl, ~~or~~ ;  
d) phenyl, ~~or~~ ;  
e) phenyl substituted with one or more halo, alkyl, haloalkyl, alkoxy or nitro, ~~or~~ ;  
f) ~~an~~ N-containing heterocyclic ~~group~~.
31. (Currently amended) The method according to claim 20, wherein  
Z is  $=NR^3$ , wherein  $R^3$  is H, an unsubstituted or substituted straight or branched alkyl, unsubstituted or substituted aryl, aralkyl group, or an aralkyl group substituted in the aryl and/or alkyl moiety,



R' is an unsubstituted or substituted straight or branched alkyl, unsubstituted or substituted aryl, aralkyl group, or an aralkyl group substituted in the aryl and/or alkyl moiety, and

A is an unsubstituted or substituted straight or branched alkyl or unsubstituted or substituted aryl group.

32. (Currently amended) A hydroxylamine derivatives of the formula (II)




a) X is oxygen,

A is C<sub>1-20</sub> straight or branched alkyl, unsubstituted or substituted aryl, unsubstituted or substituted aralkyl, naphthyl or N-containing heteroaromatic group,

Z is a chemical bond,

R' is H, C<sup>1-4</sup> alkyl or aralkyl, and


$R$  is a group of the formula (b),




where R<sup>5</sup> and R<sup>6</sup> are independently H, straight or branched alkyl, or cycloalkyl, or R<sup>5</sup> and R<sup>6</sup>, when taken together with the N-atom adjacent thereto, form a 3- to 7-membered saturated heterocyclic ring, Y<sup>6</sup> is H or -OR<sup>7</sup> wherein R<sup>7</sup> is H, -OH, k is 1, 2 or 3, and m is 1, 2, or 3, with the proviso that when A is other than alkyl and R' is H, Y<sup>6</sup> is H, or

- b) X is  $=NR^4$ , wherein  $R^4$  is H, unsubstituted or substituted alkyl, unsubstituted or substituted aryl, or unsubstituted or substituted aralkyl,  
A is unsubstituted or substituted aryl, or unsubstituted or substituted aralkyl, or cycloalkyl,  
Z is a chemical bond, oxygen or  $=NR^3$ , wherein  $R^3$  is H or unsubstituted or substituted alkyl,  
 $R'$  is unsubstituted or substituted alkyl or unsubstituted or substituted aryl, or unsubstituted or substituted aralkyl, and  
R is a group of the formula (b), wherein  $R^5$  and  $R^6$  are independently H, straight or branched alkyl, or cycloalkyl, or  $R^5$  and  $R^6$ , when taken together with the N-atom adjacent thereto, form a 3 to 7-membered saturated heterocyclic ring,  $Y^6$  is H or  $-OR^7$  wherein  $R^7$  is H, or unsubstituted or substituted alkylcarbonyl, or arylcarbonyl, k is 1, 2 or 3, and m is 1, 2 or 3, or
- c) X is oxygen,  
A is unsubstituted or substituted alkyl, unsubstituted or substituted aralkyl,  
Z is oxygen,  
 $R'$  is alkyl or aralkyl,  
R is a group of the formula (b), wherein  $R^5$  and  $R^6$  are independently H, straight or branched alkyl, or cycloalkyl, or  $R^5$  and  $R^6$ , when taken together with the N-atom adjacent thereto, form a 3- to 7-membered saturated heterocyclic ring,  $Y^6$  is H or  $-OR^7$  wherein  $R^7$  is H, or unsubstituted or substituted alkylcarbonyl, or arylcarbonyl, k is 1, 2 or 3, and m is 1, 2 or 3, or
- d) X is oxygen,  
Z is  $=NH$  and  
A is unsubstituted or substituted alkyl, cycloalkyl, unsubstituted or substituted aralkyl, phenyl or phenyl substituted with halo, alkyl, haloalkyl, alkoxy or nitro,  
 $R'$  is alkyl or aralkyl, and

33. (Currently amended) The hydroxylamine derivatives of claim 32, wherein A is phenyl, substituted phenyl or phenylalkyl.
34. (Currently amended) A pharmaceutical composition, and said composition's comprising pharmaceutically acceptable carriers and auxiliaries, for the treatment of cardiovascular, vascular, cerebral, allergic, immune, or autoimmune diseases, diseases caused by viral or bacterial infections, tumorous, skin or mucosal diseases, wherein the said composition contains 0.5 to 99.5% by weight of a hydroxylamine compound of the formula (II)



$R$  is a group of the formula (b),



- where  $R^5$  and  $R^6$  are independently H, straight or branched alkyl, or cycloalkyl, or  $R^5$  and  $R^6$ , when taken together with the N-atom adjacent thereto, form a 3 to 7-membered saturated heterocyclic ring,  $Y^6$  is H or  $—OR^7$  wherein  $R^7$  is  $H—OH$ , k is 1, 2 or 3, and m is 1, 2, or 3, with the proviso that when A is other than alkyl and  $R'$  is H,  $Y^6$  is H, or
- b) X is  $=NR^4$ , wherein  $R^4$  is H, unsubstituted or substituted alkyl, unsubstituted or substituted aryl, or unsubstituted or substituted aralkyl,
- A is unsubstituted or substituted aryl, or unsubstituted or substituted aralkyl, or cycloalkyl,
- Z is a chemical bond, oxygen or  $=NR^3$ , wherein  $R^3$  is H or unsubstituted or substituted alkyl,
- $R'$  is unsubstituted or substituted alkyl, or unsubstituted or substituted aryl, or unsubstituted or substituted aralkyl, and
- R is a group of the formula (b), wherein  $R^5$  and  $R^6$  are independently H, straight or branched alkyl, or cycloalkyl, or  $R^5$  and  $R^6$ , when taken together with the N-atom adjacent thereto, form a 3- to 7-membered saturated heterocyclic ring,  $Y^6$  is H or  $-OR^7$  wherein  $R^7$  is  $H$ , or unsubstituted or substituted alkylcarbonyl, or arylcarbonyl, k is 1, 2 or 3, and m is 1, 2 or 3, or
- c) X is oxygen,
- A is unsubstituted or substituted alkyl, unsubstituted or substituted aralkyl,
- Z is oxygen,
- $R'$  is alkyl or aralkyl,
- R is a group of the formula (b), wherein  $R^5$  and  $R^6$  are independently H, straight or branched alkyl, or cycloalkyl, or  $R^5$  and  $R^6$ , when taken together with the N-atom adjacent thereto, form a 3- to 7-membered saturated heterocyclic ring,  $Y^6$  is H or  $-OR^7$  wherein  $R^7$  is  $H$ , or unsubstituted or substituted alkylcarbonyl, or arylcarbonyl, k is 1, 2 or 3, and m is 1, 2 or 3, or
- d) X is oxygen,
- Z is  $=NH$  and

A is unsubstituted or substituted alkyl, cycloalkyl, unsubstituted or substituted aralkyl, phenyl or phenyl substituted with halo, alkyl, haloalkyl, alkoxy or nitro,

R' is alkyl or aralkyl, and

R is a group of the formula (b), wherein R<sup>5</sup> and R<sup>6</sup> are independently H, straight or branched alkyl, or cycloalkyl, or R<sup>5</sup> and R<sup>6</sup>, when taken together with the N-atom adjacent thereto, form a 3- to 7-membered saturated heterocyclic ring, Y<sup>6</sup> is H or -OH, k is 1, 2 or 3, and m is 1, 2 or 3.